Corbus Pharmaceuticals Holdings, Inc. (CRBP) completed the last patient first visit for its Phase 1b CANYON‑1 study of CRB‑913, an oral peripherally restricted CB1 inverse agonist for obesity. The 240‑patient, 16‑week, double‑blind, placebo‑controlled, dose‑ranging trial enrolled patients at 20 mg, 40 mg and 60 mg doses and is scheduled to finish in the summer of 2026, with a data readout expected shortly thereafter. The LPFV marks the final enrollment milestone, confirming that the study is on track and can proceed to the planned dosing and monitoring phases without delay.
The completion of the LPFV brings Corbus closer to the first substantive efficacy data for CRB‑913, positioning the drug as a differentiated, orally administered alternative to GLP‑1 therapies such as semaglutide and tirzepatide. In earlier Phase 1a work, CRB‑913 produced a mean 2.9% placebo‑adjusted weight loss by Day 14, and the peripherally restricted design aims to avoid the psychiatric side effects that plagued first‑generation CB1 inverse agonists. By targeting patients who are intolerant or non‑responsive to current GLP‑1 treatments, CRB‑913 could capture a sizable market segment and potentially enhance the effectiveness of existing GLP‑1 regimens when used in combination.
Corbus’s financial position supports continued development of its obesity and oncology pipelines. As of December 31 2025, the company held $163.3 million in cash, sufficient to fund operations into 2028, and had recently completed a $75 million public offering in Q4 2025. CEO Yuval Cohen noted that the encouraging data from CRB‑701 and CRB‑913 in the fourth quarter of 2025 set the stage for a potentially transformative 2026, with key data readouts anticipated this summer that should clarify the drugs’ differentiated efficacy, safety profiles and commercial opportunities.
The company’s broader pipeline includes CRB‑701, an antibody‑drug conjugate for oncology that has received FDA Fast Track designation, underscoring Corbus’s diversified approach to drug development and its potential to generate multiple revenue streams in the future.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.